Bitopertin
Bitopertin is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against sodium- and chloride-dependent glycine transporter 1. In addition, it is known to target sodium- and chloride-dependent glycine transporter 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 2 | 6 | — | — | 9 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | 1 | — | — | — | 1 |
| Thalassemia | D013789 | EFO_1001996 | D56 | — | 1 | — | — | — | 1 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | — | — | — | 1 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 12 | — | — | — | — | 12 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Drug misuse | D000076064 | — | — | 1 | — | — | — | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | — | — | — | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bitopertin |
| INN | bitopertin |
| Description | Bitopertin (developmental code names RG1678; RO-4917838) is a glycine reuptake inhibitor which was under development by Roche as an adjunct to antipsychotics for the treatment of persistent negative symptoms or suboptimally controlled positive symptoms associated with schizophrenia. Research into this indication has been largely halted as a result of disappointing trial results.
|
| Classification | Small molecule |
| Drug class | glycine transporter/reuptake inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@H](Oc1ccc(S(C)(=O)=O)cc1C(=O)N1CCN(c2ncc(C(F)(F)F)cc2F)CC1)C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 845614-11-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1171829 |
| ChEBI ID | — |
| PubChem CID | 24946690 |
| DrugBank | — |
| UNII ID | Q8L6AN59YY (ChemIDplus, GSRS) |
Target
Agency Approved
SLC6A9
SLC6A9
Organism
Homo sapiens
Gene name
SLC6A9
Gene synonyms
NCBI Gene ID
Protein name
sodium- and chloride-dependent glycine transporter 1
Protein synonyms
glyT-1, solute carrier family 6 (neurotransmitter transporter, glycine), member 9, Solute carrier family 6 member 9
Uniprot ID
Mouse ortholog
Slc6a9 (14664)
sodium- and chloride-dependent glycine transporter 1 (P28571)
Alternate
SLC6A5
SLC6A5
Organism
Homo sapiens
Gene name
SLC6A5
Gene synonyms
GLYT2, NET1
NCBI Gene ID
Protein name
sodium- and chloride-dependent glycine transporter 2
Protein synonyms
norepinephrine transporter 1, solute carrier family 6 (neurotransmitter transporter, glycine), member 5, Solute carrier family 6 member 5
Uniprot ID
Mouse ortholog
Slc6a5 (104245)
sodium- and chloride-dependent glycine transporter 2 (Q91ZQ2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 386 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use